Targeted antimicrobial therapy for dental caries

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,000,000.00
Award Year:
2007
Program:
STTR
Phase:
Phase II
Contract:
2R42MD001831-02
Award Id:
75574
Agency Tracking Number:
MD001831
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
C3 JIAN, INC., 872 3-CRABS RD, SEQUIM, WA, 98382
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
613464267
Principal Investigator:
MAXWELL ANDERSON
(360) 681-5033
MAXSCRUISER@GMAIL.COM
Business Contact:
MAXWELL ANDERSON
() -
maxscruiser@gmail.com
Research Institution:
UNIVERSITY OF CALIFORNIA - LOS

UNIVERSITY OF CALIFORNIA LOS ANGELES
Office of Research Administration
LOS ANGELES, CA, 90095 3498

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Extensive research in the past 50 years has demonstrated that Dental caries is a microbial infection caused by a limited number of cariogenic bacteria (i.e., Streptococcus mutans) that co-reside with over 400 other non- harmful/commensal microbial species in the Dental plaque. The current anti-microbial strategies used to treat Dental caries have consisted primarily of mechanical removal of Dental plaque or generalized killing of oral bacteria with anti-bacterial compound s. These remove all, kill-all approaches have shown limited efficacy, since a cleaned tooth surface provides an equal opportunity for commensal and pathogenic bacteria to re-colonize in the non-sterile environment of the oral cavity. Cariogenic bacteri a usually re-dominate the Dental plaque after the treatment and start another cycle of cariogenesis. This study proposes to develop a targeted antimicrobial therapy against Streptococcus mutans. By selectively killing or inhibiting the cariogenic bacteria within a pathogenic Dental plaque, a non-pathologic, commensal microbial community could be established. This healthy plaque would then serve as an effective barrier to prevent the subsequent colonization of cariogenic bacteria on the tooth surface, lead ing to a sustained anti-caries therapeutic effect. With the Phase-I funding support, a new class of S. mutans-selective molecules, called specifically (or selectively) targeted antimicrobial peptides (STAMPs) were successfully developed. The Phase- II stud ies aim to optimize, improve and perfect these promising molecules into actual therapeutic products against oral microbial infections. The Specific Aims are: 1): Anti-S. mutans STAMPs will be optimized for stronger killing ability, higher binding affinity, smaller size and suitable stability in saliva; 2) Extensive cellular toxicity, genetic toxicity, and animal toxicity studies will be performed to examine the safety issue of the anti-S. mutans STAMPs; and 3) The effective and safe anti-S. mutans STAMPs wi ll be chosen to test their ability to convert the diseased plaque to healthy plaque , using the established in vitro, ex vivo and in vivo assays developed in UCLA, Colgate-Palmolive and C3 Jian Inc. The successful execution of this research plan will fu rther improve the STAMP technology and lead to the development of a targeted antimicrobial therapy against cariogenic bacterium Streptococcus mutans. Phase III follow up works will include human clinical trials to evaluate the safety and efficacy of these STAMP-based therapeutic agents.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government